Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2019 May 3. pii: S1083-8791(19)30282-4. doi: 10.1016/j.bbmt.2019.04.026. [Epub ahead of print]

PMID:
31054983
2.

Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.

Carrillo-Cruz E, García-Lozano JR, Márquez-Malaver FJ, Sánchez-Guijo FM, Montero Cuadrado I, Ferra I Coll C, Valcárcel D, López-Godino O, Cuesta M, Parody R, López-Corral L, Alcoceba M, Caballero-Velázquez T, Rodríguez-Gil A, Bejarano-García JA, Ramos TL, Pérez-Simón JA.

Clin Cancer Res. 2019 Aug 1;25(15):4616-4623. doi: 10.1158/1078-0432.CCR-18-3875. Epub 2019 May 1.

PMID:
31043390
3.

Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT.

Gonzalez-Rodriguez AP, Lopez-Corral L, Fajardo DFM, Gonzalez-Huerta AJ, Palomo P, Bermudez A, Ripa TZ, Santos-Diaz P, Gonzalez-Muñiz S, Zanabilli J, Ubieto AJ, de Arriba F, Arnao-Herraiz M, Sordo-Bahamonde C, López-Soto A, Gonzalez S, Rosiñol L, Mateos MV.

Bone Marrow Transplant. 2019 Apr 15. doi: 10.1038/s41409-019-0525-1. [Epub ahead of print] No abstract available.

PMID:
30988379
4.

Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.

Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D.

Bone Marrow Transplant. 2019 Jul;54(7):1176. doi: 10.1038/s41409-019-0471-y.

PMID:
30733543
5.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N.

Haematologica. 2019 May;104(5):929-936. doi: 10.3324/haematol.2018.200808. Epub 2019 Jan 17.

6.

Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.

Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D.

Bone Marrow Transplant. 2019 Jul;54(7):1133-1137. doi: 10.1038/s41409-018-0422-z. Epub 2018 Dec 13. No abstract available. Erratum in: Bone Marrow Transplant. 2019 Feb 7;:.

PMID:
30546069
7.

Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.

Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, Perez E, Lopez-Parra M, Avendaño A, Veiga A, Baile M, Arratibel N, Carrillo J, Vazquez L, Caballero MD, Gonzalez-Porras JR.

Bone Marrow Transplant. 2019 May;54(5):757-761. doi: 10.1038/s41409-018-0368-1. Epub 2018 Oct 24. No abstract available.

PMID:
30356164
8.

Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.

Gayoso J, Balsalobre P, Kwon M, Herrera P, Bermúdez A, Sampol A, Jiménez S, López-Corral L, Serrano D, Piñana JL, Pascual MJ, Heras I, Bento L, Varela R, Humala K, Zabalza A, Laiglesia A, Bastos-Oreiro M, Pérez-Corral A, Martínez-Laperche C, Buño I, Díez-Martín JL; GETH (Grupo Español de Trasplante Hematopoyético), Spain.

Eur J Haematol. 2018 Sep;101(3):332-339. doi: 10.1111/ejh.13103. Epub 2018 Aug 3.

PMID:
29846964
9.

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

Afram G, Simón JAP, Remberger M, Caballero-Velázquez T, Martino R, Piñana JL, Ringden O, Esquirol A, Lopez-Corral L, Garcia I, López-Godino O, Sierra J, Caballero D, Ljungman P, Vazquez L, Hägglund H.

Med Oncol. 2018 Apr 25;35(6):79. doi: 10.1007/s12032-018-1127-2.

10.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA.

Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.

11.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
12.

Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.

Krzeminski P, Corchete LA, García JL, López-Corral L, Fermiñán E, García EM, Martín AA, Hernández-Rivas JM, García-Sanz R, San Miguel JF, Gutiérrez NC.

Oncotarget. 2016 Dec 6;7(49):80664-80679. doi: 10.18632/oncotarget.13025.

13.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.

Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. No abstract available.

PMID:
27295268
14.

Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).

Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.

15.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1808-1815. doi: 10.1016/j.bbmt.2016.07.006. Epub 2016 Jul 25.

16.

Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.

Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, Serrano D, Piñana JL, Herrera P, Ferrá C, Pascual C, Heras I, Montesinos P, Zabalza A, Bento L, Figuera A, Buño I, Díez-Martín JL.

Bone Marrow Transplant. 2016 Oct;51(10):1307-1312. doi: 10.1038/bmt.2016.115. Epub 2016 May 9.

PMID:
27159177
17.

Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD.

Velasco-Guardado A, Mora-Soler A, López-Corral L, López-Godino O, Vázquez-López L, Blanco-Muñez O, Pérez-López E, Rodríguez-Pérez A, Caballero-Barrigón D.

Bone Marrow Transplant. 2016 Jun;51(6):819-24. doi: 10.1038/bmt.2016.31. Epub 2016 Mar 7.

PMID:
26950379
18.

Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model.

Cocho L, Fernández I, Calonge M, Martínez V, González-García MJ, Caballero D, López-Corral L, García-Vázquez C, Vázquez L, Stern ME, Enríquez-de-Salamanca A.

Invest Ophthalmol Vis Sci. 2016 Feb;57(2):746-58. doi: 10.1167/iovs.15-18615.

PMID:
26927568
19.

Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.

Labrador J, González-Rivero J, Monroy R, Lozano FS, López-Corral L, Caballero MD, Bastida JM, González-Porras JR.

Thromb Res. 2016 Jun;142:52-6. doi: 10.1016/j.thromres.2016.02.016. Epub 2016 Feb 18.

PMID:
26922092
20.

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, de la Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Bladé J, Perez-Simon JA, San Miguel JF; Spanish Myeloma Group / Program Study and Treatment of Hematological Malignancies cooperative study groups.

Blood. 2016 Mar 3;127(9):1151-62. doi: 10.1182/blood-2015-10-662320. Epub 2015 Dec 14.

21.

Gene Expression-Based Predictive Models of Graft Versus Host Disease-Associated Dry Eye.

Cocho L, Fernández I, Calonge M, Martínez V, González-García MJ, Caballero D, López-Corral L, García-Vázquez C, Vázquez L, Stern ME, Enríquez-de-Salamanca A.

Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4570-81. doi: 10.1167/iovs.15-16736.

PMID:
26200497
22.

Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma.

Alonso S, Cabrero M, Caballero JC, Dávila J, de la Calle VG, López-Godino O, López-Corral L, Pérez E, Vázquez L, Corral R, Caballero D, Del Cañizo C, Mateos MV.

Clin Case Rep. 2015 Jun;3(6):370-5. doi: 10.1002/ccr3.231. Epub 2015 Apr 9.

23.

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome.

Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, Vazquez L, Caballero D, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):828-34. doi: 10.1016/j.leukres.2015.05.003. Epub 2015 May 14.

PMID:
26009156
24.

Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant.

Labrador J, López-Corral L, Vazquez L, Sánchez-Guijo F, Guerrero C, Sánchez-Barba M, Lozano FS, Alberca I, Del Cañizo MC, Caballero D, González-Porras JR.

Br J Haematol. 2015 Jun;169(5):719-25. doi: 10.1111/bjh.13344. Epub 2015 Mar 26.

PMID:
25817436
25.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.

Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, López-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, KrÖger N, Garderet L.

Bone Marrow Transplant. 2015 Jun;50(6):802-7. doi: 10.1038/bmt.2015.45. Epub 2015 Mar 23.

PMID:
25798673
26.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, Sanz MA, Vigouroux S, Huynh A, Shimoni A, Bulabois CE, Caminos N, López-Corral L, Nagler A, Mohty M.

Haematologica. 2015 May;100(5):683-9. doi: 10.3324/haematol.2014.119339. Epub 2015 Mar 13.

27.

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, San Miguel JF.

Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7. No abstract available.

28.

GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.

Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA.

Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13.

PMID:
25310306
29.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF.

Leukemia. 2015 Mar;29(3):705-14. doi: 10.1038/leu.2014.238. Epub 2014 Aug 8.

PMID:
25102946
30.

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M.

Bone Marrow Transplant. 2014 Sep;49(9):1170-5. doi: 10.1038/bmt.2014.133. Epub 2014 Jun 30.

PMID:
24978140
31.

Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.

Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19.

32.

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

López-Corral L, Corchete LA, Sarasquete ME, Mateos MV, García-Sanz R, Fermiñán E, Lahuerta JJ, Bladé J, Oriol A, Teruel AI, Martino ML, Hernández J, Hernández-Rivas JM, Burguillo FJ, San Miguel JF, Gutiérrez NC.

Haematologica. 2014 Aug;99(8):1365-72. doi: 10.3324/haematol.2013.087809. Epub 2014 May 9.

33.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
34.

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, Díez-Campelo M, Sánchez-Guijo F, Pérez-López E, Guerrero C, Alberca I, Del Cañizo MC, Pérez-Simón JA, González-Porras JR, Caballero D.

Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24.

35.

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socié G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M.

Bone Marrow Transplant. 2014 Mar;49(3):389-96. doi: 10.1038/bmt.2013.204. Epub 2014 Jan 13.

36.

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF.

N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439.

37.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ.

Leukemia. 2014 Feb;28(2):384-390. doi: 10.1038/leu.2013.199. Epub 2013 Jul 2.

38.

Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.

Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA.

Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15.

PMID:
23772672
39.

To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors.

Parody R, Caballero D, Márquez-Malaver FJ, Vázquez L, Saldaña R, Madrigal MD, Calderón C, Carrillo E, Lopez-Corral L, Espigado I, Carmona M, López-Villar O, Pérez-Simón JA.

Eur J Haematol. 2013 Nov;91(5):448-55. doi: 10.1111/ejh.12140. Epub 2013 Oct 1.

PMID:
23710624
40.

Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.

Barba P, Valcárcel D, Pérez-Simón JA, Fernández-Avilés F, Piñana JL, Martino R, López-Anglada L, Rovira M, Garcia-Cadenas I, Novelli S, Carreras E, López Corral L, Sierra J.

Biol Blood Marrow Transplant. 2013 Apr;19(4):597-601. doi: 10.1016/j.bbmt.2012.12.018. Epub 2013 Jan 8.

41.

The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.

Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D.

Haematologica. 2013 Apr;98(4):526-32. doi: 10.3324/haematol.2012.065599. Epub 2012 Oct 12.

42.

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.

Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR.

Haematologica. 2013 Mar;98(3):437-43. doi: 10.3324/haematol.2012.069559. Epub 2012 Aug 16.

43.

Endoscopic evaluation and histological findings in graft-versus-host disease.

Velasco-Guardado A, López-Corral L, Alvarez-Delgado A, Flores-Corral T, Geijo-Martínez F, Caballero-Barrigón D, Rodríguez-Pérez A.

Rev Esp Enferm Dig. 2012 Jun;104(6):310-4. English, Spanish.

44.

Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.

Arefi M, García JL, Peñarrubia MJ, Queizán JA, Hermosín L, López-Corral L, Megido M, Giraldo P, de las Heras N, Vanegas RJ, Gutiérrez NC, Hernández-Rivas JM.

Eur J Haematol. 2012 Jul;89(1):37-41. doi: 10.1111/j.1600-0609.2012.01799.x.

PMID:
22587685
45.

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status.

López-Corral L, Sarasquete ME, Beà S, García-Sanz R, Mateos MV, Corchete LA, Sayagués JM, García EM, Bladé J, Oriol A, Hernández-García MT, Giraldo P, Hernández J, González M, Hernández-Rivas JM, San Miguel JF, Gutiérrez NC.

Leukemia. 2012 Dec;26(12):2521-9. doi: 10.1038/leu.2012.128. Epub 2012 May 8.

PMID:
22565645
46.

Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

Matarraz S, Paiva B, Diez-Campelo M, López-Corral L, Pérez E, Mateos MV, Giraldo P, Hernández MT, San Miguel JF, Orfao A; GEM Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Co-operative Study Groups.

Haematologica. 2012 Oct;97(10):1608-11. doi: 10.3324/haematol.2012.064121. Epub 2012 Apr 17.

47.

Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning.

Barba P, Martino R, Perez-Simón JA, Fernández-Avilés F, Piñana JL, Valcárcel D, Campos-Varela I, Lopez-Anglada L, Rovira M, Novelli S, Lopez-Corral L, Carreras E, Sierra J.

Bone Marrow Transplant. 2012 Oct;47(10):1343-9. doi: 10.1038/bmt.2012.25. Epub 2012 Mar 5.

PMID:
22388280
48.

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative.

Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15.

PMID:
22333880
49.

Genomic analysis of high-risk smoldering multiple myeloma.

López-Corral L, Mateos MV, Corchete LA, Sarasquete ME, de la Rubia J, de Arriba F, Lahuerta JJ, García-Sanz R, San Miguel JF, Gutiérrez NC.

Haematologica. 2012 Sep;97(9):1439-43. doi: 10.3324/haematol.2011.060780. Epub 2012 Feb 13.

50.

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N.

Haematologica. 2012 Feb;97(2):310-7. doi: 10.3324/haematol.2011.045757. Epub 2011 Oct 11.

Supplemental Content

Loading ...
Support Center